A Randomized, Investigator- and Participant-blinded, Multiple-ascending Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus and Healthy Japanese Participants
Latest Information Update: 29 Jan 2026
At a glance
- Drugs Naperiglipron (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 20 Jan 2026 Planned End Date changed from 1 Feb 2026 to 1 Mar 2026.
- 20 Jan 2026 Planned primary completion date changed from 1 Feb 2026 to 1 Mar 2026.
- 18 Nov 2025 Status changed from recruiting to active, no longer recruiting.